A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder

References

• American Psychiatric A. Diagnostic and statistical manual of mental disorders (DSM-5®). Arlington (VA): American Psychiatric Pub; 2013.
   Google Scholar
• GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1211–1259.
   PubMed Web of Science ®Google Scholar
• Saltiel PF, Silvershein DI. Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatr Dis Treat. 2015;11:875–888.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. AJP. 2006;163(11):1905–1917.
   Web of Science ®Google Scholar
• Kennedy SH, Lam RW, McIntyre RS, et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological treatments. Can J Psychiatry. 2016;61(9):540–560.
   PubMed Web of Science ®Google Scholar
• Malhi GS, Bell E, Singh AB, et al. The 2020 Royal Australian and New Zealand college of psychiatrists clinical practice guidelines for mood disorders: major depression summary. Bipolar Disord. 2020;22(8):788–804.
   PubMed Web of Science ®Google Scholar
• Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14(5):334–385.
   PubMed Web of Science ®Google Scholar
• Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology Guidelines. J Psychopharmacol. 2015;29(5):459–525.
   PubMed Web of Science ®Google Scholar
• WHO. Depression. Retrieved from: https://www.whoint/news-room/fact-sheets/detail/depression; 2020.
   Google Scholar
• WHO. Depression and Other Common Mental Disorders Global Health Estimates. Retrieved from https://appswhoint/iris/bitstream/handle/10665/254610/WHO-MSD-MER-20172-engpdf; 2017.
   Google Scholar
• Kessler RC, Sampson NA, Berglund P, et al. Anxious and non-anxious major depressive disorder in the world health organization world mental health surveys. Epidemiol Psychiatr Sci. 2015;24(3):210–226.
   PubMed Web of Science ®Google Scholar
• Liao SC, Chen WJ, Lee MB, et al. Low prevalence of major depressive disorder in Taiwanese adults: possible explanations and implications. Psychol Med. 2012;42(6):1227–1237.
   PubMed Web of Science ®Google Scholar
• Ogbo FA, Mathsyaraja S, Koti RK, et al. The burden of depressive disorders in South Asia, 1990-2016: findings from the global burden of disease study. BMC Psychiatry. 2018;18(1):333.
   PubMed Web of Science ®Google Scholar
• Cheng SH, Chen CC, Kuo HC, et al. Reimbursement changes and drug switching: are severe patients more affected? J Health Serv Res Policy. 2017;22(2):76–82.
   PubMed Web of Science ®Google Scholar
• Davari M, Khorasani E, Tigabu BM. Factors influencing prescribing decisions of physicians: a review. Ethiop J Health Sci. 2018;28(6):795–804.
   PubMed Web of Science ®Google Scholar
• Kennedy N, Foy K, Sherazi R, et al. Long-term social functioning after depression treated by psychiatrists: a review. Bipolar Disord. 2007;9(1–2):25–37.
   PubMed Web of Science ®Google Scholar
• Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opin Drug Discov. 2019;14(1):81–89.
   PubMed Web of Science ®Google Scholar
• Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43–57.
   PubMed Web of Science ®Google Scholar
• Orsolini L, Tomasetti C, Valchera A, et al. Current and future perspectives on the major depressive disorder: focus on the new multimodal antidepressant vortioxetine. CNS Neurol Disord Drug Targets. 2017;16(1):65–92.
   PubMed Web of Science ®Google Scholar
• Orsolini L, Tomasetti C, Valchera A, et al. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Expert Rev Neurother. 2016;16(5):483–495.
   PubMed Web of Science ®Google Scholar
• De Berardis D, Fornaro M, Anastasia A, et al. Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a “real-world” chart review study. Braz J Psychiatry. 2020;42(3):317–321.
   PubMed Web of Science ®Google Scholar
• Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharm. 2012;15(05):589–600.
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Chrones L, Florea I, et al. The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016;30(3):242–252.
   PubMed Web of Science ®Google Scholar
• Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012;26(11):1408–1416.
   PubMed Web of Science ®Google Scholar
• Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29(3):138–149.
   PubMed Web of Science ®Google Scholar
• Chin CN, Zain A, Hemrungrojn S, et al. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA). Curr Med Res Opin. 2018;34(11):1975–1984.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366.
   PubMed Web of Science ®Google Scholar
• Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215–223.
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar AR, Zajecka J, Jacobson W, et al. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacol. 2015;40(8):2025–2037.
   PubMed Web of Science ®Google Scholar
• McClintock SM, Husain MM, Wisniewski SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011;31(2):180–186.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharm. 2014;17(10):1557–1567.
   PubMed Web of Science ®Google Scholar
• Minhas FA, Rana RZ, Hamdani SU, et al. PREVIDA in Pakistan: impact of vortioxetine on severity, cognitive dysfunctions, and functionality in patients with major depression. J Pakistan Psychiatric Soc. 2021;18(1):22–33.
   Google Scholar
• Vieta E, Loft H, Florea I. Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder. Eur Neuropsychopharmacol. 2017;27(9):877–884.
   PubMed Web of Science ®Google Scholar
• Yang YK, Chen CS, Tsai CF, et al. A Taiwanese study on real-world evidence with vortioxetine in patients with major depression in Asia (TREVIDA). Curr Med Res Opin. 2021;37(12):2163–2173.
   PubMed Web of Science ®Google Scholar
• The University of South Florida, Florida Medicaid Drug Therapy Management Program, sponsored by the Florida Agency for Health Care Administration. 2019–2020 Florida Best Practice Psychotherapeutic Medication Guidelines for Adults; 2020.
   Google Scholar
• Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613.
   PubMed Web of Science ®Google Scholar
• Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry. 2007;4(7):28–37.
   PubMedGoogle Scholar
• Fehnel SE, Forsyth BH, DiBenedetti DB, et al. Patient-centered assessment of cognitive symptoms of depression. CNS Spectr. 2016;21(1):43–52.
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–365.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. AJP. 2006;163(1):28–40.
   Web of Science ®Google Scholar
• KPMG. The rising social and economic cost of major depression: seeing the full spectrum. https://assetskpmg/content/dam/kpmg/sg/pdf/2021/03/Depression-Spectrum-in-the-Asia-Pacificpdf; 2020.
   Google Scholar
• Ng CW, How CH, Ng YP. Managing depression in primary care. Singapore Med J. 2017;58(8):459–466.
   PubMed Web of Science ®Google Scholar
• Thatte U, Hussain S, de Rosas-Valera M, et al. Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan. Value Health. 2009;12(Suppl 3):S18–S25.
   PubMed Web of Science ®Google Scholar
• Udomratn P. Mental health and psychiatry in Thailand. Int Psychiatry. 2007;4(1):11–14.
   PubMedGoogle Scholar
• Treuer T, Liu CY, Salazar G, et al. Use of antidepressants in the treatment of depression in Asia: guidelines, clinical evidence, and experience revisited. Asia Pac Psychiatry. 2013;5(4):219–230.
   PubMed Web of Science ®Google Scholar
• Ministry of Health Malaysia. Management of Major Depressive Disorder (Second Edition). 2019.
   Google Scholar
• Reza H, Khan M. Depressive disorder: diagnosis and management in general practice in Pakistan. J Pak Med Assoc. 2003;53(10):500–505.
   PubMedGoogle Scholar
• Woods SW, Rizzo JA. Cost-effectiveness of antidepressant treatment reassessed. Br J Psychiatry. 1997;170:257–263.
   PubMed Web of Science ®Google Scholar
• Fried EI, Nesse RM. The impact of individual depressive symptoms on impairment of psychosocial functioning. PLOS One. 2014;9(2):e90311.
   PubMed Web of Science ®Google Scholar
• Christensen MC, Loft H, McIntyre RS. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: a novel dual outcome measure in depressive disorders. J Affect Disord. 2018;227:787–794.
   PubMed Web of Science ®Google Scholar
• Chokka P, Bougie J, Proulx J, et al. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study. CNS Spectr. 2019;24(6):616–627.
   PubMed Web of Science ®Google Scholar
• Jacobsen PL, Nomikos GG, Zhong W, et al. Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram. CNS Spectr. 2020;25(1):50–63.
   PubMed Web of Science ®Google Scholar